Dyne Therapeutics, Inc. DYN · Stock Open Dyne Therapeutics, Inc. in new tab
Dyne Therapeutics, Inc. Analysis (DYN)
Is Dyne Therapeutics, Inc. a good investment? Dyne Therapeutics, Inc. (DYN) is currently trading at 17.09 USD. Market analysts have a consensus price target of 37.20 USD. This suggests a potential upside from current levels.
Earnings Schedule: Dyne Therapeutics, Inc. is expected to release its next earnings report on Nov. 4, 2026. The market consensus estimate for Forward EPS is -3.33.
Investor FAQ
Does Dyne Therapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Dyne Therapeutics, Inc.?
Dyne Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 4, 2026. The company currently has a trailing EPS of -3.26.
Company Profile
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Community Discussion